E11.3523 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

Name of the Condition

• Common Name: Type 2 Diabetes with Proliferative Diabetic Retinopathy and Traction Retinal Detachment (Macula, Bilateral)
• Medical Term: Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

Summary

This condition is a severe complication of type 2 diabetes characterized by the growth of abnormal new blood vessels in the retina (proliferative diabetic retinopathy) and subsequent traction retinal detachment affecting the macula of both eyes. It arises from prolonged high blood sugar levels damaging retinal blood vessels, potentially leading to vision impairment or blindness if untreated. The combination of proliferative changes and traction detachment indicates advanced retinal damage requiring prompt management.

Causes

High blood sugar levels over time damage the small blood vessels in the retina, triggering the growth of fragile, abnormal blood vessels. These vessels can form scar tissue that pulls on the retina, leading to traction retinal detachment. This process is driven by diabetes-related vascular changes and metabolic imbalances, which disrupt normal retinal function and structure.

Risk Factors

• Poorly controlled blood glucose levels.
• Long duration of diabetes.
• Hypertension and high cholesterol.
• Smoking and obesity.
• Family history of diabetic eye disease.

Symptoms

• Sudden or gradual vision loss.
• Blurred or distorted vision.
• Floaters or dark spots in the visual field.
• Difficulty with night vision.
• Reduced central vision affecting both eyes.

Diagnosis

Diagnosis involves a comprehensive eye examination, including dilated retinal imaging (e.g., fundus photography, optical coherence tomography) to assess retinal structure and blood vessel abnormalities. Fluorescein angiography may be used to visualize abnormal blood vessel growth. Visual acuity tests and retinal mapping help confirm macular involvement and bilateral extent.

Treatment Options

Treatment focuses on stabilizing vision and preventing further damage. Options include laser photocoagulation to reduce abnormal blood vessel growth, intravitreal injections of anti-VEGF agents to inhibit vascular proliferation, and surgical intervention (e.g., vitrectomy) to repair retinal detachment. Blood sugar and blood pressure management are critical to slow disease progression.

Prognosis and Follow-Up

Prognosis depends on the severity of retinal damage and timeliness of treatment. Early intervention can preserve vision, but advanced cases may result in permanent vision loss. Regular follow-up with an ophthalmologist is essential to monitor retinal changes and adjust treatment. Long-term management of diabetes and associated conditions is necessary to reduce recurrence risk.

Complications

• Permanent vision loss or blindness.
• Recurrent retinal detachment.
• Glaucoma due to abnormal blood vessel growth.
• Cataracts, which may develop or worsen.
• Reduced quality of life due to visual impairment.

Lifestyle & Prevention

• Maintain strict blood glucose control through diet, exercise, and medication.
• Regular eye examinations, including dilated retinal checks, to detect early changes.
• Manage blood pressure and cholesterol levels.
• Avoid smoking and limit alcohol intake.
• Adopt a heart-healthy diet rich in fruits, vegetables, and whole grains.

When to Seek Professional Help

Seek immediate medical attention if you experience sudden vision changes, increased floaters, or persistent blurring in both eyes. Early evaluation by an ophthalmologist is critical to prevent irreversible damage. Do not delay care if symptoms worsen or new visual disturbances occur.

Tips for Medical Coders

Document the bilateral nature of the condition clearly in the medical record, as this distinguishes it from unilateral cases. Include details on macular involvement and traction retinal detachment to support code specificity. Ensure documentation aligns with clinical findings to validate the use of E11.3523.